WallStSmart

Seaboard Corporation (SEB)vsSanofi ADR (SNY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Sanofi ADR generates 382% more annual revenue ($47.35B vs $9.83B). SNY leads profitability with a 16.0% profit margin vs 5.9%. SEB appears more attractively valued with a PEG of 0.65. SEB earns a higher WallStSmart Score of 65/100 (B-).

SEB

Strong Buy

65

out of 100

Grade: B-

Growth: 5.3Profit: 4.5Value: 9.3Quality: 8.0
Piotroski: 5/9Altman Z: 3.59

SNY

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.5Value: 5.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SEBUndervalued (+49.9%)

Margin of Safety

+49.9%

Fair Value

$11112.70

Current Price

$4540.14

$6572.56 discount

UndervaluedFair: $11112.70Overvalued
SNYUndervalued (+25.0%)

Margin of Safety

+25.0%

Fair Value

$62.70

Current Price

$43.31

$19.39 discount

UndervaluedFair: $62.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SEB5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Price/BookValuation
0.8x10/10

Reasonable price relative to book value

EPS GrowthGrowth
277.0%10/10

Earnings expanding 277.0% YoY

Altman Z-ScoreHealth
3.5910/10

Safe zone — low bankruptcy risk

PEG RatioValuation
0.658/10

Growing faster than its price suggests

SNY4 strengths · Avg: 8.8/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Market CapQuality
$103.45B9/10

Large-cap with strong market position

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

Areas to Watch

SEB4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

Free Cash FlowQuality
$-150.00M2/10

Negative free cash flow — burning cash

SNY3 concerns · Avg: 2.3/10
Return on EquityProfitability
6.6%3/10

ROE of 6.6% — below average capital efficiency

PEG RatioValuation
3.762/10

Expensive relative to growth rate

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : SEB

The strongest argument for SEB centers on P/E Ratio, Price/Book, EPS Growth. PEG of 0.65 suggests the stock is reasonably priced for its growth.

Bull Case : SNY

The strongest argument for SNY centers on Price/Book, Market Cap, Operating Margin. Profitability is solid with margins at 16.0% and operating margin at 20.0%.

Bear Case : SEB

The primary concerns for SEB are Revenue Growth, Profit Margin, Operating Margin.

Bear Case : SNY

The primary concerns for SNY are Return on Equity, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

SEB profiles as a value stock while SNY is a mature play — different risk/reward profiles.

SNY carries more volatility with a beta of 0.28 — expect wider price swings.

SNY is growing revenue faster at 6.0% — sustainability is the question.

SNY generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

SEB scores higher overall (65/100 vs 51/100). SNY offers better value entry with a 25.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Seaboard Corporation

INDUSTRIALS · CONGLOMERATES · USA

Seaboard Corporation is a global agribusiness and transportation company. The company is headquartered in Merriam, Kansas.

Visit Website →

Sanofi ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Want to dig deeper into these stocks?